공시 • May 28

Myriad Genetics Highlights Data Demonstrating Broad Clinical Utility of Precise Mrd Assay At 2026 Asco Annual Meeting

Myriad Genetics announced it will share data demonstrating the utility of Myriad’s Precise MRD (molecular residual disease) test across diverse cancer types. Myriad will share evidence across six poster presentations showcasing the prognostic power of its ultrasensitive MRD assay. Several of the presentations report interim outcomes from the MONSTAR-SCREEN-3 study. In the presentation, 'Prognostic Impact of MRD Positivity at Ultra-sensitive ctDNA Levels Using a WGS-based Personalized Assay: A Pan-Cancer Analysis from MONSTAR-SCREEN-3,' 97% baseline detection was reported, with 16% of samples detected in the ultrasensitive range. Patients who were ctDNA-positive at one month post-surgery had significantly worse disease-free survival compared to those who were ctDNA-negative, suggesting that post-surgical ctDNA positivity, including at ultrasensitive levels, is strongly prognostic for recurrence risk. Other presentations focused on ovarian cancer, gastric cancer, head and neck cancer, and sarcoma also demonstrate the emerging clinical utility of ctDNA as a biomarker of recurrence and therapy response. Detecting ctDNA at very low levels consistently across multiple tumor types demonstrates that sensitivity truly matters. Precise MRD may enable a new standard in which ultra-sensitive detection translates directly into earlier, more confident clinical decision-making. Attendees can meet at the Industry Expert Theater #1 on Sun., May 31 from 9:30 to 10:30 am CDT for an introduction to the Precise MRD Test. The session will cover assay technical details and the clinical evidence across multiple solid tumors, including breast and colorectal cancers, and explore the role of highly sensitive MRD detection in oncology. Myriad presentations include: Poster 64, abstract 4081: Whole-Genome Sequencing-Based Ultra-sensitive ctDNA Molecular Residual Disease Assessment in Resectable Gastric Cancer: Results from MONSTAR-SCREEN-3; Poster 181, abstract 3044: Prognostic Impact of Positivity at Ultra-sensitive ctDNA Levels Using a WGS-based Personalized Assay: A Pan-Cancer Analysis from MONSTAR-SCREEN-3; Poster 523, abstract 6066: Clinical Validation of Ultra-Sensitive WGS-based MRD Detection in Head and Neck Squamous Cell Carcinoma: Results from MONSTAR-SCREEN-3; Poster 270, abstract 5604: The Use of Circulating Tumor DNA to Stratify the Risk of Recurrence After Surgical Debulking in Epithelial Ovarian Cancer; Poster 334, abstract 11544: Ultra-Sensitive Whole-Genome Sequencing-Based Molecular Residual Disease Detection in Resectable Sarcoma in MONSTAR-SCREEN-3; Poster 501, abstract 10540: Association between physical activity and molecular residual disease clearance in postoperative cancer patients: The SCRUM-MONSTAR LIFELOG study. Myriad tests to be highlighted at the booth include: Precise MRD (Molecular Residual Disease) Test is a tumor-informed assay that uses whole genome sequencing (WGS) to achieve ultra-sensitivity. This unique assay enables the custom selection of up to 1,000 targeted variants for deep analysis. It has impressive limits of detection and sensitivity. The test can be used to monitor circulating tumor DNA (ctDNA) levels throughout a patient’s clinical cancer care, starting immediately after diagnosis and continuing through treatment and surveillance. MyRisk Hereditary Cancer Test with RiskScore combines genetics, clinical factors (Tyrer-Cuzick), and polygenic risk to uncover insights that gene testing alone may not provide, helping offer more information to support patient decisions in breast cancer risk assessment and management. Prolaris + AI Prostate Cancer Prognostic Test is the first and only prostate cancer biomarker test to unite clinical-pathological features, an independent molecular score, and independent AI-powered digital pathology technology from Myriad’s partnership with PATHOMIQ AI. The booth will also feature Myriad’s Biopharma services which are utilized for working in conjunction with Biopharma partners to advance drug development programs from biomarker discovery through CTA, CDx development, worldwide regulatory approval and global commercialization. MyChoice CDx is the only FDA-approved homologous recombination deficiency (HRD) test specifically mentioned in ASCO guidelines for selecting patients with ovarian cancer who may benefit from PARP inhibitors. By determining comprehensive HRD status, the MyChoice CDx Test helps expand access to targeted therapy in both early and late-line settings. MSK-ACCESS is a comprehensive liquid biopsy test developed by Memorial Sloan Kettering Cancer Center (MSK). The test offers noninvasive cancer genomic profiling and disease monitoring using cell-free DNA (cfDNA) obtained from blood and other body fluids. The test is currently available for use in conjunction with Myriad’s Pharma partnerships for CTA development and CDx utilizing Myriad’s partnership with SOPHiA GENETICS. MSK-IMPACT is a solid tumor test for comprehensive genomic profiling (CGP) which delivers high-resolution profiling of complex biomarkers from DNA and RNA in a single, end-to-end workflow. The test is currently available for use in conjunction with Pharma partnerships for CTA development and CDx utilizing Myriad’s partnership with SOPHiA GENETICS. The MONSTAR-SCREEN-3 is a prospective multicenter study targeting more than 1,100 patients with solid tumors undergoing curative-intent treatment. Personalized panels were constructed using Precise MRD, incorporating up to 1,000 tumor-specific alterations identified through WGS of matched tumor tissue. Serial plasma samples were collected at baseline, post-neoadjuvant treatment (NAT) (when applicable), 1-month (1M) post-surgery, every 3 months in year 1, and every 6 months thereafter up to 2 years. Assay performance was evaluated across multiple cancer types for ctDNA detection and recurrence monitoring. The Precise MRD test provides molecular insights across the cancer care continuum. After diagnosis, the test can help clinicians determine if adjuvant treatment is needed, or if cancer has recurred. Should cancer metastasize in a patient, Precise MRD can provide molecular insights showing whether treatment is working or if a patient’s ctDNA is increasing. For baseline tests, a personalized panel is developed based on a whole-genome sequencing profile of tumor tissue, and then the panel is used to measure the ctDNA level from an initial blood draw. For ongoing monitoring, the panel measures ctDNA levels from samples collected with a frequency based on where patients are in the treatment process. Clinicians will receive an easy-to-read report that shows whether ctDNA was detected or not. If ctDNA is detected, the concentration of ctDNA is reported, which allows clinicians to see historical results of the patient’s ctDNA concentration over time.

Biotechs 이익 성장	22.8%
매출 성장률	6.0%
향후 자기자본이익률	n/a
애널리스트 커버리지	Good
마지막 업데이트	01 Jun 2026

날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2028	970	-47	N/A	N/A	6
12/31/2027	916	-51	N/A	56	9
12/31/2026	864	-71	N/A	36	9
3/31/2026	829	-400	-23	2	N/A
12/31/2025	825	-366	-26	2	N/A
9/30/2025	825	-400	-29	-2	N/A
6/30/2025	833	-395	-50	-23	N/A
3/31/2025	831	-101	-36	-6	N/A
12/31/2024	838	-127	-38	-9	N/A
9/30/2024	824	-116	-107	-70	N/A
6/30/2024	802	-155	-141	-93	N/A
3/31/2024	774	-235	-155	-96	N/A
12/31/2023	753	-263	-184	-111	N/A
9/30/2023	734	-274	-138	-63	N/A
6/30/2023	699	-248	-119	-44	N/A
3/31/2023	695	-146	-155	-93	N/A
12/31/2022	678	-112	-152	-106	N/A
9/30/2022	661	-77	-143	-108	N/A
6/30/2022	672	-18	-164	-145	N/A
3/31/2022	682	-8	-117	-100	N/A
12/31/2021	691	-27	1	19	N/A
9/30/2021	684	-57	-7	14	N/A
6/30/2021	662	-97	-26	-6	N/A
3/31/2021	566	-148	11	28	N/A
12/31/2020	557	-224	-40	-27	N/A
9/30/2020	598	-194	-25	-14	N/A
6/30/2020	639	-199	51	61	N/A
3/31/2020	761	-148	53	62	N/A
12/31/2019	813	-26	N/A	52	N/A
9/30/2019	835	-15	N/A	92	N/A
6/30/2019	851	5	N/A	84	N/A
3/31/2019	830	23	N/A	100	N/A
12/31/2018	796	26	N/A	105	N/A
9/30/2018	767	54	N/A	100	N/A
6/30/2018	744	133	N/A	116	N/A
3/31/2018	749	130	N/A	105	N/A
12/31/2017	763	126	N/A	134	N/A
9/30/2017	771	101	N/A	133	N/A
6/30/2017	729	17	N/A	106	N/A
3/31/2017	757	32	N/A	108	N/A
12/31/2016	751	63	N/A	113	N/A
9/30/2016	748	94	N/A	134	N/A
6/30/2016	741	117	N/A	166	N/A
3/31/2016	757	121	N/A	179	N/A
12/31/2015	747	108	N/A	163	N/A
9/30/2015	738	95	N/A	163	N/A
6/30/2015	723	80	N/A	141	N/A

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/06/11 13:40
종가	2026/06/11 00:00
수익	2026/03/31
연간 수익	2025/12/31

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

분석가	기관
Jack Meehan	Barclays
Derek Taller	Benchmark Company
Michael Ryskin	BofA Global Research

Myriad Genetics 향후 성장

Future 기준 점검 0/6

핵심 정보

최근 향후 성장 업데이트

Myriad Genetics, Inc. Reiterates Earnings Guidance for the Full Year 2026

Myriad Genetics, Inc. Provides Earnings Guidance for the First Quarter and Second Half of 2026; Reiterate Earnings Guidance for the Full Year 2026

Myriad Genetics, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2025 and 2026

Myriad Genetics, Inc. Reiterates Earnings Guidance for the Full-Year 2025

Myriad Genetics, Inc. Revises Financial Guidance for the Full Year of 2025

Myriad Genetics, Inc. Updates Earnings Guidance for the Year 2025

Recent updates

Myriad Genetics, Inc. Announces Appointment of Raj Jampa to Chief Technology Officer, Effective June 1, 2026

Myriad Genetics Highlights Data Demonstrating Broad Clinical Utility of Precise Mrd Assay At 2026 Asco Annual Meeting

Myriad Genetics Launches Prolaris Plus AI Test Combining Genomics And Digital Pathology Artificial Intelligence

Myriad Genetics, Inc. Reiterates Earnings Guidance for the Full Year 2026

Myriad Genetics, Inc. to Report Q1, 2026 Results on May 05, 2026

Myriad Genetics Announces Six Abstracts and Podium Presentations at AACR Annual Meeting

Myriad Genetics, Inc., Annual General Meeting, Jun 04, 2026

Myriad Genetics Announces New Data Presentations At Society of Gynecologic Oncology Annual Meeting

Myriad Genetics, Inc. Announces FDA Approval Of The MyChoice CDx Test As Companion Diagnostic For Zejula For Patients With Ovarian Cancer

Myriad Genetics, Inc. Announces the Launch of the Precise MRD

Myriad Genetics, Inc. Provides Earnings Guidance for the First Quarter and Second Half of 2026; Reiterate Earnings Guidance for the Full Year 2026

Myriad Genetics, Inc. Announces the Publication of the Analytical Validation of the Firstgene Multiple Prenatal Screen in Clinical Chemistry

Myriad Genetics, Inc. to Report Q4, 2025 Results on Feb 23, 2026

Myriad Genetics, Inc. Advances Mrd Commercialization Timeline, Bolstered by New Study Data

Myriad Genetics, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2025 and 2026

Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk®? Hereditary Cancer Test to Support Evolving Clinical Needs

Myriad Genetics to Highlight Genetic Testing Advancements at 2025 National Society of Genetic Counselors Annual Conference

Myriad Genetics, Inc. Reiterates Earnings Guidance for the Full-Year 2025

Myriad Genetics, Inc. Announces A Post-Hoc Analysis of the Precision Medicine in Mental Health Care Study

Myriad Genetics, Inc. to Report Q3, 2025 Results on Nov 03, 2025

Myriad Genetics, Inc. Adds F8, FXN Genes to Foresight Universal Plus Panel

Myriad Genetics, Inc. Announces Executive Changes, Effective October 24, 2025

Myriad Genetics, Inc. Announces Precise MRD Clinical Data Published in The Lancet Oncology

Myriad Genetics, Inc. Announces the Publication of New Meta- Analysis of Six Prospective Controlled Studies

Myriad Genetics, Inc. Announces Chief Financial Officer Changes

New Myriad Genetics, Inc. Releases Findings from Its Latest Cancer Risk Survey

Myriad Genetics, Inc. Revises Financial Guidance for the Full Year of 2025

Myriad Genetics, Inc. to Report Q2, 2025 Results on Aug 05, 2025

Myriad Genetics, Inc. Announces Early Access to the FirstGene Multiple Prenatal Screen

Myriad Genetics Shares New Clinical Data Demonstrating Sensitivity of Precise Mrd Across Multiple Cancer Types

Myriad Genetics, Inc. Announces Riskscore Study Published in JCO Precision Oncology

Myriad Genetics, Inc. Updates Earnings Guidance for the Year 2025

Myriad Genetics, Inc. to Report Q1, 2025 Results on May 06, 2025

Myriad Genetics Highlights MRD Clinical Validity Data At American Association for Cancer Research Annual Meeting

Myriad Genetics, Inc. Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations After GeneSight Testing

Myriad Genetics, Inc., Annual General Meeting, Jun 05, 2025

Myriad Genetics, Inc. Appoints Brian Donnelly as Chief Commercial Officer, Effective May 1, 2025

Myriad Genetics, Inc. Announces Chief Executive Officer Changes

Myriad Genetics, Inc. to Report Q4, 2024 Results on Feb 24, 2025

Myriad Genetics, Inc. Provides Unaudited Earnings Guidance for the Fourth Quarter and Full-Year Ended December 31, 2024 and Full-Year of 2025

Myriad Genetics Elects Mark S. Davis as New Board Member

Third quarter 2024 earnings released: US$0.24 loss per share (vs US$0.75 loss in 3Q 2023)

Myriad Genetics, Inc. Reports Impairment Charges for the Third Quarter Ended September 30, 2024

New minor risk - Share price stability

Myriad Genetics, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Now 22% undervalued after recent price drop

Myriad Genetics, Inc. Provides Earnings Guidance for the Third Quarter 2024 and Reaffirms Earnings Guidance for the Full-Year 2024

Myriad Genetics, Inc. to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual Conference

Independent Director recently sold €245k worth of stock

Insider recently sold €288k worth of stock

Second quarter 2024 earnings released: US$0.41 loss per share (vs US$1.42 loss in 2Q 2023)

Myriad Genetics, Inc. Raises Earnings Guidance for the Full Year 2024

Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer, Effective September 3, 2024

Myriad Genetics, Inc. to Report Q2, 2024 Results on Aug 06, 2024

New minor risk - Financial position

CEO, President & Director recently sold €5.3m worth of stock

Myriad Genetics, Inc. Reiterates Earnings Guidance for the Full Year 2024

First quarter 2024 earnings released: US$0.29 loss per share (vs US$0.67 loss in 1Q 2023)

Myriad Genetics, Inc. to Report Q1, 2024 Results on May 07, 2024

Myriad Genetics, Inc. Provides Revenue Guidance for the First Quarter 2024

Full year 2023 earnings released: US$3.18 loss per share (vs US$1.39 loss in FY 2022)

Myriad Genetics, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Myriad Genetics, Inc. Appoints George Daneker as President and Chief Clinical Officer of Oncology, Effective March 18, 2024

Myriad Genetics, Inc. (NasdaqGS:MYGN) agreed to acquire Select assets of Intermountain Precision Genomics.

Myriad Genetics, Inc. Announces Chief Financial Officer Changes

Myriad Genetics, Inc. has completed a Follow-on Equity Offering in the amount of $109.999996 million.

New minor risk - Shareholder dilution

Myriad Genetics, Inc. Provides Financial Guidance for 2023 and 2024

Third quarter 2023 earnings released: US$0.75 loss per share (vs US$0.43 loss in 3Q 2022)